Online Exclusives

Trials & Filings in Brief: Sept. 25, 2013

By Gil Roth | September 25, 2013

Acorda, Amarin, Bayer, Cardiome, Cornerstone, KemPharm, Merck Serono and Mylan

Phase II
Cornerstone begins trial for myelodysplastic syndrome . . . read more

Acorda enrolls for spinal injury trial . . . read more

Phase III
Merck Serono to conduct cancer immunotherapy trial . . . read more

Generics
Mylan sued over first-to-file challenge of Savella . . . read more

Outcomes
Amarin enrolls 6,000+ in REDUCE-IT CV trial . . . read more

Approvals
Cardiome gains Brinavess approval in Turkey . . . read more

Bioequivalence
KemPharm's abuse-resistant opioid shows equivalence to RLD . . . read more

Filings
Bayer receives orphan status for riociguat . . . read more

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important